Association among serum fetuin-a level, coronary artery calcification, and bone mineral densitometry in maintenance hemodialysis patients

Artificial Organs

Volumn 33, Issue 10, 2009, Pages 844-854

  Kirkpantur, Alper ^a   Altun, Bulent ^a   Hazirolan, Tuncay ^b   Akata, Deniz ^b   Arici, Mustafa ^a   Kirazli, Serafettin ^c   Turgan, Cetin ^a  

^a Department of Internal Medicine   (Turkey)

^b Department of Radiology ^*  (Turkey)

^c HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Coronary artery caicincation; Hemodialysis; Retuin a; Uone minerai density

Indexed keywords

BIOMINERALIZATION; BLOOD VESSELS; BODY FLUIDS; BONE; COMPUTERIZED TOMOGRAPHY; HEART; HEMODIALYZERS; MAINTENANCE; MINERALS;

BONE MINERAL DENSITY; CORONARY ARTERIES; CORONARY ARTERY CAICINCATION; CORONARY ARTERY CALCIFICATION; HAEMODIALYSIS; HEALTHY CONTROLS; HEMODIALYSIS PATIENT; LUMBAR SPINES; RETUIN-A; UONE MINERAI DENSITY;

DIALYSIS;

FETUIN A;

ADULT; ARTERY CALCIFICATION; ARTICLE; ATHEROSCLEROTIC PLAQUE; BONE DENSITOMETRY; BONE DENSITY; CONTROLLED STUDY; CORONARY ARTERY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ELECTRON BEAM TOMOGRAPHY; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; PRIORITY JOURNAL;

EID: 72449198563     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2009.00814.x     Document Type: Article

References (52)

1. 1. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients: a link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39:695-701. (Pubitemid 34158168)
2. 2. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam, computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996;27:394-401. (Pubitemid 26075849)
3. 3. Goodman WG, Goldin J, Kuizon BD, et al. Coronaryartery calcification in young adults with, end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342: 1478-1483 (Pubitemid 30318271)
4. Chertow GM, Burke SK, Raggi P, for the Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-252
5. 5. Blacher J, Guérin AP, Pannier B, Marchais SJ, London. GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in. end-stage renal disease. Hypertension 2001;38:938-942 (Pubitemid 34258697)
6. 6. Cannata-Andia JB, Rodriguez-Garcia M, Carrillo-Lopez N, Naves-Diaz M, Diaz-Lopez B. Vascular calcifications: pathogenesis, management, and impact on clinical outcomes. J Am Soc Nephrol 2006;17:S267-73. (Pubitemid 44865260)
7. 7. Schäfer C, Heiss A, Schwarz A, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J. Clin Invest 2003;112: 357-366 (Pubitemid 38063764)
8. 8. Fontaine MA, Albert A, Dubois B, Saint-Remy A, Rorive G. Fracture and bone mineral density in hemodialysis patients. Clin Nephrol 2000;54:218-226 (Pubitemid 30690560)
9. 9. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V. Aortic calcification, and the risk of osteoporosis and fractures. J. Clin Endocrinol Metab 2004;89:4246-4253 (Pubitemid 39244420)
10. Dziegielewska KM, Brown WM. Fetuin. Heidelberg: SpringerVerlag, 1995.
11. 11. Ketteier M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003;361:827-833 (Pubitemid 36331846)
12. Triffitt JT, Gebauer U, Ashton BA, Owen ME, Reynolds JJ. Origin of plasma alpha2HS-glycoprotein and its accumulation in bone. Nature 1976;262:226-227
13. Keeley KW, Sitarz EE. Identification and quantitation, of alpha 2-HS-glycoprotein in the mineralized matrix of calcified plaques of atherosclerotic human aorta. Atherosclerosis 1985;55:63-69
14. 14. Schinke T, Amendt C, Trindl A, Poschke O, Muller-Esterl W, Jahnen-Dechent W. The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem 1996;271:20789-20796 (Pubitemid 26281865)
15. Yang F, Schwartz Z, Swain LD, Lee CC, Bowman BH, Boyan BD. Alpha 2-HS-glycoprotein: expression in chondrocytes and augmentation of alkaline phosphatase and phospholipase A2 activity. Bone 1991;12:7-15.
16. 16. Demetriou M, Binkert C, Sukhu B, Tenenbaum HC, Dennis JW. Fetuin/α2-HS glycoprotein is a transforming growth factor-β type II receptor mimic and cytokine antagonist. J Biol Chem 1996;271:12755-12761 (Pubitemid 26175845)
17. 17. Szweras M, Liu D, Partridge EA, et al. α2-HS Glycoprotein/ fetuin, a transforming growth factor-β/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. Biol Chem 2002;22:19991-19997 (Pubitemid 34967522)
18. 18. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. J Am Soc Nephrol 1996;7:728-736 (Pubitemid 27466006)
19. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volumeKt/V: an analysis of error. J Am Soc Nephrol 1993;4:1205-1213
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoproteins cholesterol in plasma without use of the ultracentrifuge. Clin Chem 1972; 18:499-502.
21. Chobanian AV, Bakris GL, Black HR, et al. Joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572
22. 22. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J. Am Coll Cardiol 1990;15:827-832 (Pubitemid 20101575)
23. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929-1936
24. 24. Taal MW, Masud T, Green D, Cassidy MJD. Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant 1999;14:1922-1928 (Pubitemid 29358889)
25. 25. Nakashima A, Yorioka N, Tanji C, et al. Bone mineral density may be related to atherosclerosis in hemodialysis patients. Osteoporos Int 2003;14:369-373 (Pubitemid 36919217)
26. Rodriguez-Garda M, Naves Diaz M, Cannata Andia JB. Bone metabolism, vascular calcifications and mortality: associations beyond mere coincidence. J Nephrol 2005;18:458-463
27. Rodriguez-Garcia M, Gomez Alonso C, Naves Diaz M, et al. Vascular calcification, bone mass, vertebral fractures and mortality in hemodialysis patients. J Am Soc Nephrol 2004;15:175A. [Abstract],
28. Price PA, Roublick AM, Williamson MK. Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with, ibandronate. Kidney Int 2006;70:1577-1583
29. 29. Davies MR, Lund RJ, Mathew S, Hruska KA. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J. Am Soc Nephrol 2005;16:917-928 (Pubitemid 41710302)
30. 30. Stompór T, Pasowicz M, Sullowicz W, et al. An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. Am J Kidney Dis 2003;41:20311. (Pubitemid 36043368)
31. 31. Jung HH, Kim SW, Han H. Inflammation, mineral metabolism, and progressive coronary artery calcification in patients on haemodialysis. Nephrol Dial Transplant 2006;21:1915-1920 (Pubitemid 43985720)
32. 32. Stenvinkel P, Wang K, Qureshi AR, et al. Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int 2005;67:2383-2392 (Pubitemid 41623401)
33. Hermans MM, Brandenburg V, Ketteler M, et al. Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrol Dial Transplant 2006;21:1293-1299
34. 34. Ganesan K, Teklehaimanot S, Iran TH, Asuncion. M, Norris K. Relationship of C-reactive protein and bone mineral density in community-dwelling elderly females. J Natl Med Assoc 2005;97:329-333 (Pubitemid 40315936)
35. Malluche H, Monier-Faugere CM. Risk of adynamic bone disease in dialyzed patients. Kidney Int 1992;42(Suppl. 38): S62-7.
36. 36. Coen G, Manni M, Agnoli A, et al. Cardiac calcifications: fetuin-A. and other risk factors in hemodialysis patients. ASAIO J 2006;52:150-156 (Pubitemid 44309497)
37. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(4 Suppl. 3):S1-201.
38. 38. Moe SM, Reslerova M, Ketteler M, et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005;67:2295-2304 (Pubitemid 41623389)
39. Moe SM, Chen XN, O'Neill KD, et al. Fetuin-A and matrix gla protein (MGP) are important inhibitors of vascular calcification in CKD. J Am Soc Nephrol 2003;14:692. [Abstract],
40. 40. Mehrotra R, Westenfeld R, Christenson P, et al. Serum fetuin-A in non-dialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int 2005;67:1070-1077 (Pubitemid 41623332)
41. Binkert C, Demetriou M, Sukhu B, Szweras M, Tenenbaum HC, Dennis JW. Regulation of osteogenesis by fetuin. J Biol Chem 1999;274:28514-28520
42. 42. Reynolds JL, Skepper JN, McNair R, et al. Multifunctional roles for serum protein. fetuin-A in inhibition, of human vascular smooth muscle cell calcification. J Am Soc Nephrol 2005;16:2920-2930 (Pubitemid 44743490)
43. 43. Adams CS, Mansfield K, Perlot RL, Shapiro IM. Matrix regulation of skeletal cell apoptosis. Role of calcium and phosphate ions. J Biol Chem 2001;276:20316-20322 (Pubitemid 37411110)
44. 44. Coen G, Ballanti P, Balducci A, et al. Renal osteodystrophy: a-heremans schmid glycoprotein/fetuin-A, matrix GLA protein serum, levels, and bone histomorphometry. Am J Kidney Dis 2006;48:106-113 (Pubitemid 43912955)
45. Martin KJ, Fukagawa M, Malluche HH. Diagnosis of bone and. mineral disorders. In: Olgaard K, ed. Clinical Guide to Bone and Mineral Metabolism in CKD, 1st Edition. New York: National Kidney Foundation, 2006;45-73.
46. 46. Barnas U, Schmidt A, Seidl G, Kaider A, Pietschmann P, Mayer G. A comparison of quantitative computed tomography and dual X-ray absorptiometry for evaluation of bone mineral density in patients on chronic hemodialysis. Am J Kidney Dis 2001;37:1247-1252 (Pubitemid 32525162)
47. 47. Johnson DW, Mclntyre HD, Brown A. The role of DEXA bone densitometry in evaluating renal osteodystrophy in continuous ambulatory peritoneal dialysis patients. Perk Dial Int 1996;16:34-40. (Pubitemid 26044617)
48. Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol Dial Transplant 2008;23:586-593
49. Piraino B, Chen T, Cooperstein L, Segre G, Puschett J. Fractures and vertebral, bone mineral density in patients with, renal osteodystrophy. Clin Nephrol 1998;30:57-62.
50. Moe SM, Yu BO, Sprague SM. Maintenance of bone mass in patients receiving dialytic therapy. Am J Kidney Dis 1993; 22:300-307
51. Eknoyan G, Levin A, Levin NW, National Kidney Foundation. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(Suppl. 3):1-201.
52. Meunier P, Courpron P, Giroux JM, Edouard C, Bernard J, Vignon G. Bone histomorphometry as applied to research on osteoporosis and to the diagnosis of "hyperosteoidosis states." Calcif Tissue Res 1976;21:354-360